Edasalonexent

Summary

Edasalonexent (CHEMBL3786673) is a phase-3 clinical-stage small molecule; indicated across 2 conditions including duchenne muscular dystrophy and type 2 diabetes mellitus.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Small molecule
• Indications: 2 conditions
• Clinical trials: 5
• Chemistry: 490.7 Da · C31H42N2O3

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL3786673
Name	Edasalonexent
Type	Small molecule
Max phase	3
FDA approved	no
PubChem CID	44626120
Molecular formula	C31H42N2O3
Molecular weight	490.7
InChIKey	JQLBBYLGWHUHRW-KUBAVDMBSA-N

SMILES: CC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CCC(=O)NCCNC(=O)C1=CC=CC=C1O

IUPAC name: N-[2-[[(4Z,7Z,10Z,13Z,16Z,19Z)-docosa-4,7,10,13,16,19-hexaenoyl]amino]ethyl]-2-hydroxybenzamide

Also known as: Cat 1004, CAT 1004, Cat-1004, CAT-1004, CAT1004, Edasalonexent, Edasalonexento, EDASALONEXENT

Patent coverage: 60 distinct patent families (178 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

2 indications (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
Duchenne muscular dystrophy	3	MONDO:0010679	MONDO:0010679
type 2 diabetes mellitus	1	MONDO:0005148	MONDO:0005148

Clinical trials

Total trials: 5.

Phase distribution

Phase	Trials
PHASE3	2
PHASE1	2
PHASE1/PHASE2	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT03703882	PHASE3	COMPLETED	Phase III Study of Edasalonexent in Boys With Duchenne Muscular Dystrophy
NCT03917719	PHASE3	TERMINATED	An Open-Label Extension Study of Edasalonexent in Boys With Duchenne Muscular Dystrophy
NCT02439216	PHASE1/PHASE2	COMPLETED	Phase 1/2 Study in Boys With Duchenne Muscular Dystrophy
NCT01511900	PHASE1	COMPLETED	A Multiple Ascending Dose Study of CAT-1004 in Patients With Type 2 Diabetes
NCT01670773	PHASE1	COMPLETED	A Study of CAT-1004 Biomarkers in Healthy Subjects

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).